SRRK
Scholar Rock Holding Corp.
October 5, 2026 · pre-market open
- Rarity
- 1.69
- Peak move
- −8.82%
- Float cap
- $4.0B
Scholar Rock is a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy and additional rare, severe, and debilitating neuromuscular diseases. It develops monoclonal antibodies that selectively target latent forms of growth factors, including apitegromab for SMA and facioscapulohumeral muscular dystrophy, and SRK-439 for rare neuromuscular diseases.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
no events · 0 from SEC or newswire · 0 timed with the moveNot searched yet.A blank here does not mean there was no cause.